Clinical Trials Results - National Cancer Institute

Skip to content

NCI Home

Cancer Topics

Clinical Trials

Cancer Statistics

Research & Funding

News

About NCI


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -9 of 9 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Active				18 and over				Pharmaceutical / Industry				20040212 NCT00109031


2.		A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Active				18 to 70				Pharmaceutical / Industry				20050219 NCT00434161


3.		A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Palifermin (rHuKGF) in the Reduction of Acute Graft Versus Host Disease in Subjects With Hematologic Malignancies Undergoing Allogeneic Marrow/PBPC Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care				Active				18 and over				Pharmaceutical / Industry				20040213 NCT00189488


4.		Palifermin After Haploidentical PBSCT

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Approved-not yet active				18 to 65				Other				EudraCt: 2007-003241-32 NCT00570999

First Published: 8/4/2008


5.		Phase II Randomized Study of Palifermin in Preventing Chemotherapy- and/or Radiotherapy-Induced Oral Mucositis in Pediatric Patients Undergoing Autologous or Allogeneic Hematopoietic Stem Cell Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care, Treatment				Approved-not yet active				1 to 16				NCI				COG-ACCL0521 ACCL0521, COG-ACCL0521, NCT00728585


6.		Busulfan, Melphalan, and Fludarabine With Peri-Transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care, Treatment				Active				Under 65				Other				08-008 NCT00629798


7.		A Phase 1 Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				1 to 16				Pharmaceutical / Industry				20010133 NCT00460421

Last Modified: 8/23/2008 First Published: 5/23/2007


8.		Phase I Pilot Study of High-Dose Melphalan and Palifermin in Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation for Stage II or III Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Supportive care, Treatment				Active				18 and over				NCI				WSU-2006-119 WSU 2006-119, NCT00482846


9.		Dose Escalation Study Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Supportive care				Active				2 to 18				Other				PALSCT NCT00701688

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute